Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

UNBELIEVABLE: 10x genomics | History Defined

3 Genomic Research Companies Pioneering Personalized Medicine

With vast potential, contribution to rare disease discovery and management, and adoption of AI, the genomic research market is thriving. Hence, fundamentally solid genomic research stocks Agilent Technologies (A), Illumina (ILMN), and 10x Genomics (TXG) could be ideal buys. Read more.

1 Cathie Wood Stock With 55% Upside Potential

1 Cathie Wood Stock With 55% Upside Potential

This Ark Invest biotech stock pick, with 55% potential upside, garnered a vote of confidence from Jefferies last week.

Benzinga's Top Ratings Upgrades, Downgrades For July 15, 2022

Benzinga's Top Ratings Upgrades, Downgrades For July 15, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

10x Genomics's Return On Capital Employed Overview

10x Genomics (NASDAQ:TXG) brought in sales totaling $114.50 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 129.89%, resulting in a loss of $42.41 million.

10x Genomics: Q1 Earnings Insights

10x Genomics (NASDAQ:TXG) reported its Q1 earnings results on Wednesday, May 4, 2022 at 04:05 PM. Here's what investors need to know about the announcement.

4 Analysts Have This to Say About 10x Genomics

Analysts have provided the following ratings for 10x Genomics (NASDAQ:TXG) within the last quarter:

10x Genomics Posts Topline Growth Of 8%, Reaffirms FY22 Guidance

10x Genomics (NASDAQ: TXG) reported

inkl

Read news from The Economist, FT, and more,
with one subscription

10x Genomics: Q1 Earnings Insights

10x Genomics: Q1 Earnings Insights

10x Genomics (NASDAQ:TXG) reported its Q1 earnings results on Wednesday, May 4, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings 10x Genomics missed estimated earnings by 22.58%, reporting an EPS of $-0.38 versus an estimate of $-0.31.

Teladoc vs. 10x Genomics: Which Beaten-Down Health Information Services Stock Is a Better Buy?

Teladoc vs. 10x Genomics: Which Beaten-Down Health Information Services Stock Is a Better Buy?

Today I'll analyze and compare Teladoc (TDOC) and 10x Genomics (TXG) to determine which stock is a better buy.

10x Genomics Shares Plunge On Disappointing Q4 Earnings, FY22 Outlook

10x Genomics Shares Plunge On Disappointing Q4 Earnings, FY22 Outlook

10x Genomics Inc (NASDAQ: TXG)

Recap: 10x Genomics Q4 Earnings

Recap: 10x Genomics Q4 Earnings

10x Genomics (NASDAQ:TXG) reported its Q4 earnings results on Wednesday, February 16, 2022 at 04:05 PM. Here's what investors need to know about the announcement.

A Preview Of 10x Genomics's Earnings

A Preview Of 10x Genomics's Earnings

10x Genomics (NASDAQ:TXG) is set to give its latest quarterly earnings report on Wednesday, 2022-02-16. Here's what investors need to know before the announcement. Analysts estimate that 10x Genomics will report an earnings per share (EPS) of $-0.09.

1

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Delta Air Lines

Truist Securities

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play